Pharmaceutical Stocks To Follow Today - June 12th

Eli Lilly and Company, Pfizer, D-Wave Quantum, Novo Nordisk A/S, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies involved in the research, development, manufacturing and distribution of drugs and medical therapies. Their share prices often fluctuate in response to clinical trial results, regulatory approvals or setbacks, patent expirations and shifts in healthcare policy. Investors watch pharmaceutical stocks for both growth potential—driven by successful drug launches—and income, as many of these companies pay dividends. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of Eli Lilly and Company stock traded up $0.18 on Thursday, reaching $808.79. The stock had a trading volume of 1,260,843 shares, compared to its average volume of 3,939,877. The stock has a market capitalization of $766.52 billion, a P/E ratio of 69.07, a P/E/G ratio of 1.40 and a beta of 0.41. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a 50 day moving average price of $771.74 and a 200 day moving average price of $800.91.

Read Our Latest Research Report on LLY

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Shares of PFE stock traded up $0.33 during trading hours on Thursday, hitting $24.81. The company's stock had a trading volume of 28,591,606 shares, compared to its average volume of 46,867,418. The company has a 50 day moving average of $22.96 and a 200 day moving average of $24.98. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $141.05 billion, a PE ratio of 17.60, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. Pfizer has a 12-month low of $20.92 and a 12-month high of $31.54.

Read Our Latest Research Report on PFE

D-Wave Quantum (QBTS)

D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.

Shares of NYSE:QBTS traded down $0.53 during midday trading on Thursday, hitting $16.00. The company had a trading volume of 38,820,111 shares, compared to its average volume of 77,474,836. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -38.10 and a beta of 1.49. The business's 50-day simple moving average is $11.18 and its 200-day simple moving average is $8.06. D-Wave Quantum has a twelve month low of $0.75 and a twelve month high of $19.76.

Read Our Latest Research Report on QBTS

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Novo Nordisk A/S stock traded up $1.92 during mid-day trading on Thursday, reaching $80.65. 7,606,584 shares of the company's stock were exchanged, compared to its average volume of 9,479,798. The company has a fifty day moving average of $66.58 and a 200-day moving average of $80.16. The company has a market cap of $361.92 billion, a P/E ratio of 24.51, a P/E/G ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Read Our Latest Research Report on NVO

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE ABBV traded up $0.25 during midday trading on Thursday, hitting $191.75. 3,038,561 shares of the company's stock were exchanged, compared to its average volume of 7,011,973. The firm's fifty day simple moving average is $183.78 and its 200-day simple moving average is $187.32. The company has a market cap of $338.71 billion, a PE ratio of 79.90, a P/E/G ratio of 1.62 and a beta of 0.50. AbbVie has a twelve month low of $163.52 and a twelve month high of $218.66. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55.

Read Our Latest Research Report on ABBV